Compare TGLS & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | NKTR |
|---|---|---|
| Founded | 1984 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2011 | 1996 |
| Metric | TGLS | NKTR |
|---|---|---|
| Price | $41.87 | $73.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $63.33 | ★ $146.67 |
| AVG Volume (30 Days) | 251.6K | ★ 629.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $370,984,000.00 | $307,711,000.00 |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $33.17 | ★ N/A |
| Revenue Growth | 17.98 | ★ 86.00 |
| 52 Week Low | $37.52 | $25.35 |
| 52 Week High | $74.57 | $109.00 |
| Indicator | TGLS | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 55.50 |
| Support Level | $41.54 | $64.28 |
| Resistance Level | $47.37 | $75.82 |
| Average True Range (ATR) | 2.04 | 2.63 |
| MACD | -0.44 | 0.18 |
| Stochastic Oscillator | 8.08 | 65.13 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.